Acute ischemic stroke treatment in a nutshell

More documents

Recommendations

Info

DABIGATRAN • 1000 stroke patients treated with dabigatran over warfarin for 1 year – 150 mg BD: 7 fewer strokes, same bleeding rate – 110 mg BD: 5 fewer strokes, 14 fewer bleeds
RIVAROXABAN AF + high risk for embolism (53% prior stroke) ROCKET-AF: randomised, blinded • RIVAROXABAN 20 mg OM vs warfarin (INR 2-3) – Per protocol: stroke and non-CNS systemic embolism (1.70% vs. 2.15%, p=0.015), 21% relative risk reduction • Non-interior • No proof of superiority – Intent to treat (ITT): (2.12% vs. 2.42%) • Non-inferior • Superior • Any bleeding: No increased risk (14.91% vs. 14.52%, p=0.442) • Major bleeding: Comparable (3.60% vs. 3.45%, p=0.576) • ICH: Fewer (0.49% vs. 0.74%, p=0.019)
Page 1 and 2: Acute ischemic stroke treatment in
Page 3 and 4: REPERFUSION TIME IS BRAIN An estima
Page 5 and 6: Reperfusion of salvageable tissue
Page 7 and 8: Improved neurological & functional
Page 9 and 10: Acute intravenous alteplase
Page 11 and 12: • BENEFIT RCT EVIDENCE
Page 13 and 14: TIME IS BRAIN • At 3 months, OR f
Page 15 and 16: Antithrombotic therapy: Antiplatele
Page 17 and 18: Stroke Unit Management • What is
Page 19 and 20: Acute ischaemic stroke treatment st
Page 21 and 22: Antithrombotic agents • Antiplate
Page 23 and 24: Antiplatelets in long-term secondar
Page 25 and 26: Which antiplatelet Acceptable optio
Page 27 and 28: Which antiplatelet better-Combinati
Page 29 and 30: Cilostazol (CSPS II) • Randomised
Page 31 and 32: Anticoagulation in long-term second
Page 33 and 34: Anticoagulants Dosing Monitoring SE
Page 35 and 36: WARFARIN Secondary prevention: Prio
Page 37: DABIGATRAN AF + high risk for embol
Page 41 and 42: APIXABAN AF patients could not tole
Page 43 and 44: Other indications for anticoagulati
Page 45 and 46: Good Side: Beneficial Effects • R
Page 47 and 48: One of many concerns Don’t forget
Page 49 and 50: Great population benefit in view of
Page 51 and 52: Management of Hypertension, Diabete
Page 53 and 54: Should all post-stroke patients be
Page 55 and 56: Should all post-stroke patients be
Page 57 and 58: Which antihypertensives to use Law,
Page 59 and 60: Which antihypertensive to use - Com
Page 61 and 62: Which antihypertensive to use - Com
Page 63 and 64: What is the target BP - Upper limit
Page 65 and 66: What is the target BP - Lower limit
Page 67 and 68: Diabetes • Diabetes is a risk fac
Page 69 and 70: Why DM control in stroke patients 4
Page 71 and 72: How tight should glycemic control b
Page 73 and 74: How tight should glycemic control b
Page 75 and 76: Dyslipidemia • Modest relationshi
Page 77 and 78: Statins and ischemic stroke - Meta-
Page 79 and 80: Should all stroke patients be on st
Page 81 and 82: BP control in secondary stroke prev
Page 83 and 84: Lipid control in secondary stroke p

Acute ischemic stroke treatment in a nutshell

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?